YD6-18132-77012
3 vaccinations
3 coded responses
27 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 460 / IN
- Registered
- 2020-12-26
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-26
Registered in v-safe
-
2020-12-26
Dose 1 — Pfizer-BioNTech
-
2020-12-27
Survey response — days 1–6 daily, dose 1MedDRA: Exercise tolerance decreased — Feeling: Good · Site: PainFree text: Decrease in running staminaMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2020-12-28
Survey response — days 1–6 daily, dose 1MedDRA: Decreased appetite — Feeling: GoodFree text: Decreased appetiteMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2020-12-29
- 2020-12-31
- 2021-01-02
- 2021-01-09
-
2021-01-16
Dose 2 — Pfizer-BioNTech
-
2021-01-16
Health check-in — day 0, dose 2Feeling: Good · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2021-01-17
- 2021-01-18
- 2021-01-20
- 2021-01-21
- 2021-01-22
- 2021-01-23
- 2021-01-30
- 2021-02-06
- 2021-02-13
- 2021-02-20
- 2021-02-27
- 2021-04-17
- 2021-07-19
-
2021-09-13
Dose 3 — Pfizer-BioNTech
- 2021-09-29
- 2021-10-04
- 2021-10-11
- 2021-10-20
- 2021-10-25
- 2021-12-15
-
2022-03-16
Survey response — 6 months, dose 3MedDRA: Emergency care, Hysterectomy, Intensive care, Postpartum haemorrhage — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: Symptoms: Post-partum hemorrhage. Critical condition. Required emergency hysterectomy. · Healthcare visit (other): ICU, ORMedDRA releases: 2024-11 · check-in free text available
-
2022-03-16
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prHospitalization · 1 call case(s)
- 2022-03-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-26 | Pfizer-BioNTech | |
| 2 | 2021-01-16 | Pfizer-BioNTech | |
| 3 | 2021-09-13 | Pfizer-BioNTech | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-03-16 | Unsuccessful |
Free text
Release 1 — days 1–6 daily, dose 1
Systemic reaction (other): Decrease in running stamina
Systemic reaction (other): Decreased appetite
Release 11 — 6 months, dose 3
Symptoms: Post-partum hemorrhage. Critical condition. Required emergency hysterectomy.
Healthcare visit (other): ICU, OR
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Intensive care | · | · | ✓ |
| SD | Emergency care | · | · | ✓ |
| SD | Hysterectomy | · | · | ✓ |
| SD | Postpartum haemorrhage | · | · | ✓ |
| SRO | Asthenia | ○ | ○ | ○ |
| SRO | Decreased appetite | ✓ | ✓ | ✓ |
| SRO | Exercise tolerance decreased | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release